GenTrust LLC Invests $7.60 Million in Natera, Inc. (NASDAQ:NTRA)

GenTrust LLC purchased a new position in Natera, Inc. (NASDAQ:NTRA) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 48,014 shares of the medical research company’s stock, valued at approximately $7,601,000.

Several other institutional investors have also recently made changes to their positions in the company. Whipplewood Advisors LLC bought a new position in shares of Natera in the fourth quarter worth $149,000. ARK Investment Management LLC increased its holdings in shares of Natera by 29.1% in the fourth quarter. ARK Investment Management LLC now owns 887,711 shares of the medical research company’s stock worth $140,525,000 after purchasing an additional 200,008 shares during the period. Y Intercept Hong Kong Ltd increased its holdings in shares of Natera by 211.9% in the fourth quarter. Y Intercept Hong Kong Ltd now owns 31,144 shares of the medical research company’s stock worth $4,930,000 after purchasing an additional 21,160 shares during the period. Arcadia Investment Management Corp MI bought a new position in shares of Natera in the fourth quarter worth $147,000. Finally, Boston Financial Mangement LLC purchased a new position in Natera in the fourth quarter worth $225,000. Institutional investors own 99.90% of the company’s stock.

Natera Trading Up 2.9 %

NASDAQ NTRA opened at $160.56 on Thursday. The company has a quick ratio of 4.23, a current ratio of 4.39 and a debt-to-equity ratio of 0.33. Natera, Inc. has a twelve month low of $73.93 and a twelve month high of $183.00. The firm has a market capitalization of $21.20 billion, a PE ratio of -91.23 and a beta of 1.66. The stock’s 50 day moving average is $167.59 and its 200 day moving average is $146.60.

Insider Activity at Natera

In other Natera news, CEO Steven Leonard Chapman sold 78,553 shares of the business’s stock in a transaction on Wednesday, January 22nd. The stock was sold at an average price of $164.97, for a total value of $12,958,888.41. Following the sale, the chief executive officer now directly owns 267,629 shares of the company’s stock, valued at approximately $44,150,756.13. The trade was a 22.69 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider John Fesko sold 663 shares of the business’s stock in a transaction on Thursday, February 6th. The stock was sold at an average price of $177.77, for a total value of $117,861.51. Following the completion of the sale, the insider now directly owns 156,044 shares in the company, valued at $27,739,941.88. This trade represents a 0.42 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 295,772 shares of company stock worth $49,741,699 over the last ninety days. 7.60% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several research analysts recently issued reports on the stock. Sanford C. Bernstein upped their target price on shares of Natera from $160.00 to $200.00 and gave the stock an “outperform” rating in a research report on Friday, January 10th. Morgan Stanley upped their target price on shares of Natera from $132.00 to $176.00 and gave the stock an “overweight” rating in a research report on Thursday, November 14th. JPMorgan Chase & Co. upped their target price on shares of Natera from $160.00 to $200.00 and gave the stock an “overweight” rating in a research report on Friday, December 13th. TD Cowen upped their target price on shares of Natera from $155.00 to $175.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. Finally, Canaccord Genuity Group reiterated a “buy” rating and issued a $180.00 target price on shares of Natera in a research report on Wednesday. One equities research analyst has rated the stock with a sell rating and sixteen have given a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $170.94.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.